A Phase 1 open label trial of intravenous administration of TAEK-VAC-HerBy vaccine in
patients with advanced brachyury and/or HER2- expressing cancer. The study will be completed
in 2 stages. In Stage 1 patients will be enrolled and treated according to a 3+3 dose
escalation scheme. Up to 4 dose levels will be explored to determine the recommended dose of
TAEK-VAC-HerBy for Stage 2 of the trial. Stage 2 will enroll either chordoma patients for
treatment with TAEK-VAC-HerBy alone, or HER2- positive breast and gastric/gastroesophageal
junction cancer patients for combination treatment of TAEK-VAC-HerBy vaccine and therapeutic
HER2 antibodies (trastuzumab, pertuzumab). Patients in both stages will receive
TAEK-VAC-HerBy intravenously, every three weeks, three administrations in total.
Chordoma, Breast Cancer, Gastric/Gastroesophageal Junction Cancer, Ovarian Cancer, Prostate Cancer, Colorectal Cancer, Pancreatic Cancer, Hepatocellular Cancer, Merkel Cell Cancer, Small Cell Lung Cancer
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.